711 related articles for article (PubMed ID: 29958564)
1. Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease.
Guilcher GMT; Truong TH; Saraf SL; Joseph JJ; Rondelli D; Hsieh MM
Semin Hematol; 2018 Apr; 55(2):87-93. PubMed ID: 29958564
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. The range of haploidentical transplant protocols in sickle cell disease: all haplos are not created equally.
Kassim AA; DeBaun MR
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):532-541. PubMed ID: 38066894
[TBL] [Abstract][Full Text] [Related]
4. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.
Hsieh MM; Fitzhugh CD; Weitzel RP; Link ME; Coles WA; Zhao X; Rodgers GP; Powell JD; Tisdale JF
JAMA; 2014 Jul; 312(1):48-56. PubMed ID: 25058217
[TBL] [Abstract][Full Text] [Related]
5. A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation.
Kean LS; Durham MM; Adams AB; Hsu LL; Perry JR; Dillehay D; Pearson TC; Waller EK; Larsen CP; Archer DR
Blood; 2002 Mar; 99(5):1840-9. PubMed ID: 11861303
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic stem cell transplantation for adult sickle cell disease in the era of universal donor availibility.
Aslam HM; Yousuf S; Kassim A; Iqbal SM; Hashmi SK
Bone Marrow Transplant; 2018 Nov; 53(11):1390-1400. PubMed ID: 29728697
[TBL] [Abstract][Full Text] [Related]
7. Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease.
Wiebking V; Hütker S; Schmid I; Immler S; Feuchtinger T; Albert MH
Ann Hematol; 2017 Aug; 96(8):1373-1377. PubMed ID: 28573314
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of matched sibling donor hematopoietic stem cell transplantation for severe sickle cell disease with myeloablative conditioning and intermediate-dose of rabbit anti-thymocyte globulin.
Soni S; Gross TG; Rangarajan H; Baker KS; Sturm M; Rhodes M
Pediatr Blood Cancer; 2014 Sep; 61(9):1685-9. PubMed ID: 24740582
[TBL] [Abstract][Full Text] [Related]
9. Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease.
Krishnamurti L; Kharbanda S; Biernacki MA; Zhang W; Baker KS; Wagner JE; Wu CJ
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1270-8. PubMed ID: 18940682
[TBL] [Abstract][Full Text] [Related]
10. Infusion of Host-Derived Unlicensed NK Cells Improves Donor Engraftment in Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation.
Alvarez M; Pierini A; Simonetta F; Baker J; Maas-Bauer K; Hirai T; Negrin RS
Front Immunol; 2020; 11():614250. PubMed ID: 33488624
[TBL] [Abstract][Full Text] [Related]
11. Good engraftment after reduced intensity targeted busulfan-based conditioning and matched related donor hematopoietic cell transplantation in hemoglobinopathies.
Klink M; Felber M; Zeilhofer U; Hauri-Hohl M; Schmugge M; Drozdov D; Güngör T
Pediatr Blood Cancer; 2024 Jul; 71(7):e30988. PubMed ID: 38613166
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience.
Zaidman I; Rowe JM; Khalil A; Ben-Arush M; Elhasid R
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1043-1048. PubMed ID: 27016193
[TBL] [Abstract][Full Text] [Related]
13. Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease and Thalassemia: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation.
Shenoy S; Angelucci E; Arnold SD; Baker KS; Bhatia M; Bresters D; Dietz AC; De La Fuente J; Duncan C; Gaziev J; King AA; Pulsipher MA; Smith AR; Walters MC
Biol Blood Marrow Transplant; 2017 Apr; 23(4):552-561. PubMed ID: 28065838
[TBL] [Abstract][Full Text] [Related]
14. Bone Marrow Transplantation after Nonmyeloablative Treosulfan Conditioning Is Curative in a Murine Model of Sickle Cell Disease.
Devadasan D; Sun CW; Westin ER; Wu LC; Pawlik KM; Townes TM; Goldman FD
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1554-1562. PubMed ID: 29684562
[TBL] [Abstract][Full Text] [Related]
15. Nonmyeloablative Matched Sibling Donor Hematopoietic Cell Transplantation in Children and Adolescents with Sickle Cell Disease.
Guilcher GMT; Monagel DA; Nettel-Aguirre A; Truong TH; Desai SJ; Bruce A; Shah RM; Leaker MT; Lewis VA
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1179-1186. PubMed ID: 30772511
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now.
Hsieh MM; Fitzhugh CD; Tisdale JF
Blood; 2011 Aug; 118(5):1197-207. PubMed ID: 21628400
[TBL] [Abstract][Full Text] [Related]
17. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease.
Hsieh MM; Kang EM; Fitzhugh CD; Link MB; Bolan CD; Kurlander R; Childs RW; Rodgers GP; Powell JD; Tisdale JF
N Engl J Med; 2009 Dec; 361(24):2309-17. PubMed ID: 20007560
[TBL] [Abstract][Full Text] [Related]
19. Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease.
Bhatia M; Jin Z; Baker C; Geyer MB; Radhakrishnan K; Morris E; Satwani P; George D; Garvin J; Del Toro G; Zuckerman W; Lee MT; Licursi M; Hawks R; Smilow E; Baxter-Lowe LA; Schwartz J; Cairo MS
Bone Marrow Transplant; 2014 Jul; 49(7):913-20. PubMed ID: 24797180
[TBL] [Abstract][Full Text] [Related]
20. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease.
Strocchio L; Zecca M; Comoli P; Mina T; Giorgiani G; Giraldi E; Vinti L; Merli P; Regazzi M; Locatelli F
Br J Haematol; 2015 Jun; 169(5):726-36. PubMed ID: 25818248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
